A Form 4 filed on November 9, 2026 discloses that Raj Jampa, Chief Technology Officer of Myriad Genetics Inc (NASDAQ:MYGN), was granted a time-based stock option covering 58,560 shares of common stock on November 6, 2026 as a one-time retention award.

Key Highlights

  • Grant date: November 6, 2026, with an exercise price of $5.92 per share, equal to the closing price of common stock on that date.
  • Option size: 58,560 shares of common stock underlie the non-qualified stock option.
  • Vesting schedule: The option vests in full on November 6, 2029, subject to continued service through that date.
  • Expiration: The option expires on November 6, 2036.
  • Award type: Described as a one-time non-qualified stock option granted as a retention award under the 2026 Employee, Director and Consultant Equity Incentive Plan.
  • Price of derivative security: $0 at grant, as reported in the filing.
  • Beneficial ownership following transaction: 58,560 derivative securities held directly.

Raj Jampa Receives Cliff-Vesting Retention Option at Myriad Genetics

According to the Form 4 filed with the SEC on November 9, 2026, Myriad Genetics Inc granted its Chief Technology Officer, Raj Jampa, a time-based non-qualified stock option on November 6, 2026. The filing states the grant was made under the company's 2026 Employee, Director and Consultant Equity Incentive Plan and is characterized as "a one-time non-qualified stock option granted as a retention award."

The filing reports the exercise price as $5.92 per share, which the filing specifies "equals the closing price of the Issuer's common stock on November 6, 2026, the grant date." The option covers 58,560 shares of common stock and carries an expiration date of November 6, 2036. Per the filing, the option "vests and becomes exercisable in full on November 6, 2029, subject to the Reporting Person's continued service through that date and the terms and conditions of the Plan and the applicable award agreement," making it a single cliff-vesting structure rather than a phased schedule.

No non-derivative securities transactions appear in Table I of the filing. The price of the derivative security at the time of the grant is listed as $0. Following the reported transaction, Jampa beneficially owns 58,560 derivative securities directly, according to the filing. The form was signed by Justin Hunter on behalf of Raj Jampa and dated November 9, 2026.

What Was Disclosed

Myriad Genetics CTO Raj Jampa received a one-time retention stock option for 58,560 shares at an exercise price of $5.92, granted November 6, 2026, vesting in full on November 6, 2029, and expiring November 6, 2036, under the company's 2026 equity incentive plan.